



Impacting Reproductive  
Care Worldwide

**Officers**

Marcelle I. Cedars, MD  
*President*

Michael A. Thomas, MD  
*President-Elect*

Paula Amato, MD  
*Vice President*

Hugh S. Taylor, MD  
*Immediate Past President*

Catherine Racowsky, PhD  
*Past President*

James Toner, MD, PhD  
*Secretary - Treasurer*

**Administration**

Jared C. Robins, MD, MBA  
*Executive Director*

Sean Tipton, MA  
*Chief Advocacy and Policy Officer*

Dan Carre, CPA, MBA  
*Chief Financial Officer*

D. Lee Pearce, MSW, MSHA  
*Chief Operating Officer*

Chevis Shannon, DrPH, MPH, MBA, MERC  
*Chief Education & Science Officer*

Senate Committee on Judiciary  
PO Box 94183  
Baton Rouge, LA 94183

Dear Chair Foil, Vice Chair Abraham, and Minority Member Barrow,

On behalf of the American Society for Reproductive Medicine (ASRM), I am writing to express strong opposition to [SB 388](#) which would curtail the reproductive rights of the residents of Louisiana and leave some facing life-threatening risk.

ASRM is a multidisciplinary organization of nearly 8,000 professionals dedicated to the advancement of the art, science, and practice of reproductive medicine. Distinguished members of ASRM include obstetricians and gynecologists, urologists, reproductive endocrinologists, embryologists, mental health professionals and others.

SB 388 seeks to further restrict the people of Louisiana's access to abortion to include medication abortion. What the bill does not take into account is both the medical necessity and efficacy of the procedure. Evidence-based practice, for which ASRM and major medical groups have all voiced support, shows that medication abortion is safe and cost-effective to the patient and the state up to the first nine weeks of pregnancy. For survivors of trauma, the ability to manage their care in a safe setting is crucial to their emotional health. Perhaps most critically, for Louisianans experiencing miscarriage, the same pills used in a medication abortion are used in clinical practice to manage a non-viable pregnancy up to 13 weeks and the effects of an early miscarriage. Criminalizing and banning these medications as proposed in SB 388 would put the women of Louisiana at risk.

I strongly urge you to oppose the passage of SB 388.

For more information, feel free to contact me or Sean Tipton, our Chief Advocacy and Policy officer at [Stipton@asrm.org](mailto:Stipton@asrm.org) or 202-421-5112.

Sincerely,

Marcelle I. Cedars, MD  
President  
American Society for Reproductive Medicine